We stimulate the growth of ambitious and innovative ...C 04062020.pdf · entrepreneurial and...
2
Health & Care 04 06 2020 For the ageing, health- and cost-conscious society. Gimv at a glance We stimulate the growth of ambitious and innovative companies and guide them in their transformation into the market leader in their niche. We regard ourselves as a temporary, but solid and experienced partner of our portfolio companies, each of which having a strong growth ambition. INVESTMENT PORTFOLIO EUR BILLION YEARS OFFICES 1.2 PORTFOLIO COMPANIES 53 OF EXPERIENCE IN PRIVATE EQUITY SINCE 1997 40 4 CONNECTED CONSUMER HEALTH & CARE SMART INDUSTRIES SUSTAINABLE CITIES Focus on 4 platforms GET TO KNOW US ON gimv.com Belgium Gimv NV Karel Oomsstraat 37 2018 Antwerpen [email protected] Netherlands Gimv Nederland Holding BV WTC The Hague Prinses Margrietplantsoen 87 2595 BR Den Haag [email protected] France Gimv France SAS 83, rue Lauriston 75116 Paris [email protected] Germany Gimv Promenadeplatz 12 80333 München [email protected] Investment approach and added value Investment criteria flexible and agile investor; strong balance sheet and access to long-term permanent capital expertise in companies at various stages of development familiar with the entire business life cycle multidisciplinary international teams reinforced by a broad international network active shareholder, involved in board entrepreneurial and innovative companies with strong growth potential small to medium-sized businesses with an enterprise value of up to EUR250 million investment tickets from EUR5 million to EUR50 million companies active in Benelux, France and DACH countries companies with a strong management, a clear business vision and a strategy based on sustainable value creation WITH MULTIDISCIPLINARY TEAMS INVESTING IN COMPANIES ACTIVE IN BENELUX, FRANCE AND DACH COUNTRIES
Transcript of We stimulate the growth of ambitious and innovative ...C 04062020.pdf · entrepreneurial and...
Health & Care04 0
6 20
20
For the ageing, health- and cost-conscious society.
Gimv at a glance
We stimulate the growth of ambitious and innovative companies and guide them in their transformation into the market leader in their niche. We regard ourselves as a temporary, but solid and experienced partner of our portfolio companies, each of which having a strong growth ambition.
INVESTMENT PORTFOLIO
EUR BILLION YEARS
OFFICES
1.2PORTFOLIO COMPANIES
53OF EXPERIENCE IN PRIVATE EQUITY
SINCE 1997
40
4
CONNECTED CONSUMER
HEALTH & CARE
SMART INDUSTRIES
SUSTAINABLE CIT IES
Focus on4 platforms
GET TO KNOW US ON gimv.com
Belgium
Gimv NVKarel Oomsstraat 372018 Antwerpen
Netherlands
Gimv Nederland Holding BVWTC The HaguePrinses Margrietplantsoen 872595 BR Den Haag
France
Gimv France SAS83, rue Lauriston75116 Paris
Germany
GimvPromenadeplatz 1280333 München
Investment approach and added value Investment criteria
flexible and agile investor; strong balance sheet and
access to long-term permanent capital
expertise in companies at various stages of development
familiar with the entire business life cycle
multidisciplinary international teams reinforced by a broad
international network
active shareholder, involved in board
entrepreneurial and innovative companies with strong growth
potential
small to medium-sized businesses with an enterprise value
of up to EUR250 million
investment tickets from EUR5 million to EUR50 million
companies active in Benelux, France and DACH countries
companies with a strong management, a clear business
vision and a strategy based on sustainable value creation
WITH MULTIDISCIPL INARY TEAMS INVESTING IN COMPANIES ACTIVE IN BENELUX , FRANCE AND DACH COUNTRIES
Investment focus
The challenges facing our health & care system are considerable: the ageing population, an increasing number of chronic diseases, better-informed patients and breakthrough technology continue to push up the demand for but also the cost of health care. This trend offers significant investment opportunities into pioneering biotechnology companies, innovative medical technology providers or leading businesses in the health care services space.
Focused clinics
Homecare
Integrated elderly care
Dedicated H&C suppliers
Dental
Medical imaging
Digital health
Drug & platform development
Cell & gene therapy
Vaccines
Diagnostic tests
Medical devices
Consumables
Small equipment
Digital platforms & e-health
Services Biotech Medtech
Portfolio
Team
Investment stages
by spineart
Michaël VlemmixAssociate
Bart DielsManaging Partner Head Health & Care
Thomas HarthAssociate
Gautier LefebvrePrincipal
Elderd LandPartner
PatrickVan BenedenPartner
HiddeVan KerckhovenPrincipal
Philippv. HammersteinPartner
Biotech / Biopharma
Medtech
Health & Care Services
Concept Product/Services Revenue Profit Mature
Pre-clinical Earlyclinical
Lateclinical
Pre-revenue
Growthstage
Growthstage
Pre-profit
Pre-profit
Buy-out
Bram VanparysPartner
Belgium
Development of innovative formulations of crop
protection products
Ireland
Connected health medical device
Belgium
Distributor of medical equipment and
consumables
France
Thermal resorts
France
Innovative antibody therapeutics for
immuno-oncology
Belgium
Development of ophthalmic implants for glaucoma
patients
France
Plastic medical devices
Switzerland
Orthopedic implants
Netherlands
Group of specialised clinics
Germany
Induction of antigen-specific immune tolerance
Netherlands
Provider of specialty pharmaceuticals
Netherlands and Switzerland
Development of a neurostimulation therapy for
Spinal Cord Injury
Germany
Service providers in incontinence care
Switzerland
Group of medical clinics
Netherlands
Specialised medical homecare (hospital to home)
Netherlands
Specialised outplacement clinic
Maximilian von den Hoff Associate
Belgium
Developer of cancer-targeted radiopharmaceuticals
Lars TimmerAssociate
Germany
Development of transcatheter aortic valves
KevinKleinAssociate
ChristophKocherAnalyst
